Cost-effectiveness of neonatal screening for Duchenne muscular dystrophy : how does this compare to existing neonatal screening for metabolic disorders ?
Costs of screening a series of 18,132 newborn males for Duchenne muscular dystrophy (DMD) in Canada were evaluated.
The final aim of neonatal screening for DMD is the avoidance of additional cases in the families identified.
Total costs to avoid one case of DMD were estimated at Cdn. $172,000, while the incremental costs were found to be $83,000.
Reagent costs, test sensitivity, efficacy of screening and compliance with genetic advice were identified as factors crucial for cost-effectiveness.
Costs of neonatal screening for DMD are compared with costs of neonatal screening for inborn metabolic disorders.
It is found that the two programmes are similar in costs.
Earlier predictions of inordinate costs of screening for DMD are refuted.
Mots-clés Pascal : Dystrophie musculaire progressive Duchenne, Analyse coût efficacité, Etude comparative, Dépistage, Nouveau né, Homme, Système nerveux pathologie, Neuromusculaire pathologie, Maladie héréditaire, Economie santé, Canada, Amérique du Nord, Amérique, Métabolisme pathologie, Programme sanitaire
Mots-clés Pascal anglais : Duchenne muscular dystrophy, Cost efficiency analysis, Comparative study, Medical screening, Newborn, Human, Nervous system diseases, Neuromuscular diseases, Genetic disease, Health economy, Canada, North America, America, Metabolic diseases, Sanitary program
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0555123
Code Inist : 002B17H. Création : 199406.